Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Takeda-led COVID-19 plasma product to begin trial this month

share with twitter share with LinkedIn share with facebook
09/17/2020 | 05:23am EDT

An experimental COVID-19 therapy using blood plasma, developed by Japan's Takeda Pharmaceutical Co and its partners, is scheduled to begin a late-stage clinical trial after initial delays.

The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States, is seeking to recruit 500 participants from the United States, Britain, Argentina and Denmark, according to posting on a website run by the U.S. government's National Institutes of Health (NIH).

The NIAID is an institute of the NIH.

The study, due to begin this month, seeks to compare outcomes from the plasma product to those from the drug Remdesivir and a placebo.

The Takeda-led group, known as the CoVIg-19 Plasma Alliance, had originally sought to begin trials in July. A Takeda representative said further questions about the study should be directed to the NIAID.

The institute did not immediately respond to a request for comment.

The alliance, which includes Biotest AG, CSL Behring, and Octapharma Plasma, is working on a hyperimmune globulin therapy derived from convalescent plasma. It offers a standardized dose of antibodies and does not need to be limited to patients with matching blood types.

Clinical supplies of the treatment were produced at Takeda's facility in the U.S. state of Georgia and at CSL Behring's facility in Bern, Switzerland.

By Rocky Swift


Stocks mentioned in the article
ChangeLast1st jan.
BIOTEST AKTIENGESELLSCHAFT -0.75% 26.4 Delayed Quote.38.54%
EURO / ARGENTINE PESO (EUR/ARS) 0.51% 92.6703 Delayed Quote.37.21%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.34% 3500 End-of-day quote.-19.21%
US DOLLAR / ARGENTINE PESO (USD/ARS) 0.17% 78.12 Delayed Quote.29.75%
share with twitter share with LinkedIn share with facebook
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/21TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Opening of First Plasm..
BU
10/15Nikkei flat as coronavirus resurgence in Europe hits sentiment
RE
10/15Japan stocks fall as risks on several fronts unsettle investors
RE
10/14TAKEDA PHARMACEUTICAL : Accelerates Digital Transformation with Accenture and AW..
AQ
10/13TAKEDA PHARMACEUTICAL : - Safety and Efficacy of Subcutaneous Entyvio Sustained ..
AQ
10/13TAKEDA PHARMACEUTICAL : Accelerates Digital Transformation with Accenture and AW..
AQ
10/13TAKEDA PHARMACEUTICAL : Accelerates Digital Transformation with Accenture and AW..
BU
10/12Takeda group begins manufacturing COVID-19 plasma treatment ahead of approval
RE
10/12TAKEDA PHARMACEUTICAL : Safety and Efficacy of Subcutaneous Entyvio® (Vedolizuma..
BU
10/09GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
More news
Financials
Sales 2021 3 268 B 31 200 M 31 200 M
Net income 2021 198 B 1 895 M 1 895 M
Net Debt 2021 3 935 B 37 569 M 37 569 M
P/E ratio 2021 40,6x
Yield 2021 5,14%
Capitalization 5 471 B 52 214 M 52 236 M
EV / Sales 2021 2,88x
EV / Sales 2022 2,61x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 443,85 JPY
Last Close Price 3 500,00 JPY
Spread / Highest target 85,7%
Spread / Average Target 55,5%
Spread / Lowest Target 17,1%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-19.21%52 003
JOHNSON & JOHNSON-0.54%381 970
ROCHE HOLDING AG-5.33%280 343
PFIZER INC.-4.47%207 994
MERCK & CO., INC.-12.91%200 341
NOVARTIS AG-16.62%186 175